A

Avalo Therapeutics
D

AVTX

13.380
USD
-0.48
(-3.46%)
مغلق
حجم التداول
25,020
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
304,909,488
المقالات
المزيد

العنوان: Avalo Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.